# Maria Rita Migliorino

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/maria-rita-migliorino/

## Facts

| Field | Value |
| --- | --- |
| Citations | 5,175 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 31 |
| i10-index | 50 |
| Last Known Institution | Nini Hospital |
| OpenAlex ID | https://openalex.org/A5113798762 |
| Works | 80 |

## Researcher papers

- [Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/dacomitinib-versus-gefitinib-as-first-line-treatment-for-patients-with-egfr/)
- [Pretreatment Quality of Life and Functional Status Assessment Significantly Predict Survival of Elderly Patients With Advanced Non—Small-Cell Lung Cancer Receiving Chemotherapy: A Prognostic Analysis of the Multicenter Italian Lung Cancer in the Elderly Study](https://scholariq.org/papers/pretreatment-quality-of-life-and-functional-status-assessment-significantly/)
- [Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and <i>EGFR</i>-Activating Mutations](https://scholariq.org/papers/improvement-in-overall-survival-in-a-randomized-study-that-compared-dacomitinib/)
- [Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies](https://scholariq.org/papers/bone-and-brain-metastasis-in-lung-cancer-recent-advances-in-therapeutic/)
- [Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study](https://scholariq.org/papers/clinical-outcomes-of-patients-with-advanced-cancer-and-pre-existing-autoimmune/)
- [Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients](https://scholariq.org/papers/correlations-between-the-immune-related-adverse-events-spectrum-and-efficacy-of/)
- [Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer](https://scholariq.org/papers/bone-metastases-and-immunotherapy-in-patients-with-advanced-non-small-cell-lung/)
- [Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study](https://scholariq.org/papers/neutrophil-to-lymphocyte-ratio-nlr-platelet-to-lymphocyte-ratio-plr-and-outcomes/)
- [Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy](https://scholariq.org/papers/differential-influence-of-antibiotic-therapy-and-other-medications-on/)
- [First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status](https://scholariq.org/papers/first-line-pembrolizumab-in-advanced-non-small-cell-lung-cancer-patients-with/)
- [Intrapatient Molecular and Histologic Heterogeneity After First-generation or Second-generation TKI Therapy of NSCLC Patients](https://scholariq.org/papers/intrapatient-molecular-and-histologic-heterogeneity-after-first-generation-or/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Nini Hospital](https://scholariq.org/institutions/nini-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.